# The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

> **NCT04097769** · PHASE1 · COMPLETED · sponsor: **Waterstone Hanxbio Pty Ltd** · enrollment: 21 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HX009

## Key facts

- **NCT ID:** NCT04097769
- **Lead sponsor:** Waterstone Hanxbio Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2021-03-18
- **Final completion:** 2022-09-29
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097769, "The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04097769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*